If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGeiger Counter Regulatory News (GCL)

Share Price Information for Geiger Counter (GCL)

Share Price is delayed by 15 minutes
Get Live Data
62.00    -1.20 (-1.90%)
Bid:
61.80
Ask:
62.00
Spread: 0.20 (0.324%)
Market Cap: £73.44m
GCL Live PriceLast checked at - London Stock Exchange

Intraday Geiger Counter Share Chart

Monthly Factsheet- July 2025

22 Aug 2025 11:26

RNS Number : 4624W
Geiger Counter Ltd
22 August 2025
 

 

 

Geiger Counter Limited Plc 

 

Monthly Investor Report 22 August 2025

(All Factsheet data is at 31 July 2025)

 

The full monthly factsheet is now available on the Company's website and a summary can be found below. 

 

NCIM - Geiger Counter Ltd - Fund Page for Geiger Counter Ltd

 

 

Enquiries: 

 

For the Investment Manager 

Craig Cleland 

Manulife CQS Investment Management

0207 201 5368 

For the Company Secretary and Administrator 

R&H Fund Services (Jersey) Limited

Jane De Barros/Katie De La Cour

01534 825259/01534 825337 

 

----------------------------------------------------------------------- 

 

 

Fund Description 

 

The objective of Geiger Counter Limited is to provide investors with the potential for capital growth through investment primarily in the securities of companies involved in the exploration, development and production of energy, predominantly within the uranium industry. Up to 30% of the value of the Company's investment portfolio may be invested in other resource- related companies from outside the energy sector.

 

Portfolio Managers 

 

Keith Watson and Robert Crayfourd 

 

 

Key Advantages for the Investor 

· Access to mining assets in the uranium sector

· May benefit from embedded subscription share

· Low correlation to major asset classes

 

 

 

Key Fund Facts1 

 

 

Total Gross Assets 

£74.6m

Reference Currency 

GBP 

Ordinary Shares: 

Net Asset Value 

52.79p 

Mid-Market Price  

47.30p 

Net gearing4 

22.36% 

Discount 

(10.40%) 

 

 

Ordinary Share and NAV Performance2 

 

 

One Month 

Three Months 

One Year 

Three Years 

Five Years 

 

(%) 

(%) 

(%) 

(%) 

(%) 

NAV 

4.93 

43.61

(9.11) 

6.86

206.03

Share Price 

7.99

39.94

4.07

12.62

164.25

 

 

Commentary3 

 

This month, the Company's NAV gained 4.9%, notwithstanding a near 4% strengthening of

sterling against the dollar, and despite the spot uranium price retreating 9% to $71.1/lb over the month. The stronger contributions were made by US located assets including Ur-Energy, UEC, and Energy Fuels, whose share prices rose 15%, 28% and 59% respectively. A seeming driver to the performance of these equities was the agreement with rare earth producer, MP Minerals, to access US funding in the form of debt and equity from the Department of Defence. Canadian developer Denison also made a useful positive contribution with a share price rise of 14%. This came after the company announced additional mineral resources at its Gryphon project, the group's second potential development after its Wheeler River production, and also commenced small-scale extraction in a joint venture project with Orano, in which it has a minority share. Paladin acted as a drag with the shares falling nearly 23% following a lowering of 2026 production guidance.

 

Geiger Counter's performance of 4.9% compared to sterling returns of 6.9% and -2.2% for the

Uranium Pure Play Index and Sprott Uranium Miners equity ETF, respectively. The differential in performance between Pure Play Index and the Sprott Trust had much to do with the contributions from the extremely volatile modular reactor equities, Oklo and NuScale. There share prices rose 27% and 37% respectively following the MP Minerals funding deal. Both modular reactor companies that are competing for government funding for their respective designs are not included in the Sprott ETF.

 

Elsewhere, Japanese utility Kansai Electric Power Company announced intentions to assess

construction of a new nuclear power plant in Fukui, Mihama, following the return to service of the remaining operating reactor at the site.

 

 

 

 

 

Gross Leverage2

(%)

Commitment Leverage3

(%)

Geiger Counter Ltd 

123

123

 

 

CQS (UK) LLP

4th Floor, One Strand, London WC2N 5HR, United Kingdom

T: +44 (0) 20 7201 6900 | F: +44 (0) 20 7201 1200

 

CQS (US), LLC

152 West 57th Street, 40th Floor, New York, NY 10019, US

T: +1 212 259 2900 | F: +1 212 259 2699

 

Tavistock Communications

18 St. Swithin's Lane, London EC4N 8AD

T: +44 20 7920 3150 | geigercounter@tavistock.co.uk

 

Sources: 1R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. 2R&H Fund Services Limited/DataStream, as at the last business day of the month indicated at the top of this report, total return performance net of fees and expenses based on bid prices. These include historic returns and past performance is not a reliable indicator of future results. The value of investments can go down as well as up. Please read the important legal notice at the end of this document. 3Market data sourced from Bloomberg unless otherwise stated. The Fund may since have exited some or all of the positions detailed in the commentary. 4 BMO, UxC, Company data September 2023. 5 www.eia.gov. 6CQS, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 7, 9 and 10 of Delegated Regulation 231/2013. 7CQS, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 8, 9, 10 and 11 of Delegated Regulation 3231/2013.

 

The Company has announced the fifth Subscription Rights Price of 32.70 pence on 1 May 2025. The exercise date for the fifth Subscription Right is expected to be 30 April 2026.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCBGGDIUDDDGUD
Date   Source Headline
3rd Jul 20262:42 pmRNSNet Asset Value(s)
2nd Jul 20264:51 pmRNSNet Asset Value(s)
1st Jul 20263:29 pmRNSNet Asset Value(s)
1st Jul 20268:30 amRNSShare Buyback
1st Jul 20268:15 amRNSHolding(s) in Company
30th Jun 20265:05 pmRNSNet Asset Value(s)
30th Jun 202612:20 pmRNSHolding(s) in Company
30th Jun 202611:58 amRNSRelease of Interim Report and Financial Statements
30th Jun 20269:05 amRNSShare Buyback
30th Jun 20269:03 amRNSMonthly Factsheet- May 2026
29th Jun 20264:04 pmRNSNet Asset Value(s)
29th Jun 20268:46 amRNSShare Buyback
26th Jun 202612:50 pmRNSNet Asset Value(s)
25th Jun 202612:54 pmRNSNet Asset Value(s)
24th Jun 20263:06 pmRNSNet Asset Value(s)
23rd Jun 20262:48 pmRNSNet Asset Value(s)
22nd Jun 20262:43 pmRNSNet Asset Value(s)
19th Jun 20261:11 pmRNSNet Asset Value(s)
18th Jun 20261:28 pmRNSNet Asset Value(s)
17th Jun 202611:03 amRNSNet Asset Value(s)
16th Jun 202612:06 pmRNSNet Asset Value(s)
15th Jun 20263:59 pmRNSNet Asset Value(s)
12th Jun 20263:29 pmRNSNet Asset Value(s)
11th Jun 20263:06 pmRNSNet Asset Value(s)
10th Jun 20262:44 pmRNSNet Asset Value(s)
9th Jun 20263:27 pmRNSNet Asset Value(s)
8th Jun 20263:27 pmRNSNet Asset Value(s)
5th Jun 20261:22 pmRNSNet Asset Value(s)
4th Jun 202612:02 pmRNSNet Asset Value(s)
3rd Jun 202612:22 pmRNSNet Asset Value(s)
2nd Jun 20262:04 pmRNSAppointment of Non-Executive Director
2nd Jun 20261:23 pmRNSNet Asset Value(s)
1st Jun 202612:24 pmRNSNet Asset Value(s)
29th May 20261:30 pmRNSNet Asset Value(s)
28th May 20263:31 pmRNSNet Asset Value(s)
27th May 20264:23 pmRNSNet Asset Value(s)
27th May 202611:57 amRNSMonthly Factsheet - April 2026
26th May 20265:24 pmRNSNet Asset Value(s)
22nd May 20262:06 pmRNSNet Asset Value(s)
21st May 20261:09 pmRNSNet Asset Value(s)
20th May 20263:20 pmRNSNet Asset Value(s)
19th May 20263:08 pmRNSNet Asset Value(s)
18th May 20261:36 pmRNSNet Asset Value(s)
15th May 20264:29 pmRNSPortfolio Management Update
15th May 20262:08 pmRNSNet Asset Value(s)
15th May 202612:42 pmRNSDistribution of Rump proceeds
14th May 20262:50 pmRNSNet Asset Value(s)
13th May 20262:19 pmRNSNet Asset Value(s)
13th May 20261:50 pmRNSHolding(s) in Company
12th May 20263:56 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.